A clinical study published in the European Heart Journal shows that the hunger hormone ghrelin can increase the heart’s pump capacity in patients with heart failure.
Heart failure occurs when the heart muscles are weakened, such as from myocardial infarction, reducing the ability to pump blood. Current treatments can slow disease progression, but none directly increase the heart’s pumping capacity.
Ghrelin is an endogenous hormone that has many receptors distributed in cardiac muscle tissues. It increases the appetite and stimulates the release of growth hormones. The researchers believe that its receptors are a promising target for enhancing the heart’s pumping capacity.
“Heart failure is the most common cause of hospitalisation in older generations and is associated with a poor quality of life and high mortality,” says principal investigator Lars Lund, professor at the Department of Medicine, Solna, Karolinska Institutet, and senior consultant at Karolinska University Hospital. “If we can find ways to increase the heart’s pump function, we can potentially improve life quality and prognosis for these patients.”
In this double-blind study, 30 patients with heart failure at Karolinska University Hospital’s cardiology unit were randomly assigned to two groups, receiving either active treatment with ghrelin or a placebo given intravenously for two hours. The participants were followed up after two to five days.
Pump function up by 28%
After two hours’ treatment, the cardiac output had increased by an average of 28% in the ghrelin group, (4.08 ± 1.15 to 5.23 ± 1.98 L/min) compared to a small reduction in the placebo group (4.26 ± 1.23 to 4.11 ± 1.99 L/min). The increase was from more blood being pumped per beat, as the heart rate remained unchanged or was even slightly slower. At the two- to five-day follow-up, the pump capacity was still 10% higher in the ghrelin group compared to in the placebo group.
No serious adverse reactions were seen, though the ghrelin group had slightly elevated levels of a heart-failure biomarker, which would need to be investigated further. The small size of the group makes limits the generalisability of the results.
Using mouse heart cells, the researchers observed that treatment with ghrelin increased the contractile function of the heart cells, and they identified a novel molecular mechanism for this increase. The researchers now plan to do larger clinical studies.
Source: Karolinska Institutet